Hepatitis C virus infection in patients from the haemodialysis clinic of a medical university, Plovdiv, Bulgaria
Abstract number: R2480
Atanasova M., Kardjeva V., Kicheva M., Draganov M., Stoyanov T., Kostadinova T., Mateva N., Kapon E., Murdjeva M.
Objectives: It has been reported, that patients with end-stage renal disease on dialysis therapy form a high risk group for hepatitis C virus (HCV) infection. Risk factors such as number of blood transfusions and frequent exposure to parenteral interventions have been pointed. The aim of our study was to determine the prevalence of HCV infection in a caseload of Bulgarian patients on permanent hemodialysis and to assess risk factors for HCV in this group.
Methods: All subjects were tested for HCV antibodies by ELISA method, as well as for HCV-RNA by real-time PCR. Liver function tests (ALT) were performed by routine methods and epidemiological data (age, sex, ethnic group, duration on hemodialysis, number of blood transfusions) were collected.
Results: A total of 85 patients (mean age 52.6 years; male/female: 48/37), visiting three times weekly Hemodialysis clinic of Medical University in Plovdiv were enrolled. HCV antibodies were found in 41(48.2%) and viraemia in 29 (34.1%) subjects, thus the overall prevalence of HCV (HCV antibody and/or HCV-RNA positivity) was 51.8% (44 patients). HCV viraemia was detectable in 63.4% of the anti-HCV-positive patients and in 6.8% of the anti-HCV-negative patients. Hence 3.5% of the whole study group were HCV infected, but could not be diagnosed by routine HCV antibody testing. Duration of dialysis and number of received blood transfusions were established as main risk factors for acquiring HCV infection.
Conclusion: HCV prevalence is high in hemodialysed patients and nosocomial spread of hepatitis C virus is suggested. These data indicate: (i) the need for strict adherence to infection control measures in dialysis units and (ii) the importance of screening by both PCR and serological methods at stated intervals to reveal all HCV infected patients.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|